NeoSphere (ClinicalTrials.gov Identifier: NCT00545688), an open-label phase 2 study to evaluate the efficacy of pertuzumab and trastuzumab in HER2+ IBC patients (Table 1), showed significantly higher pCR in patients treated with pertuzumab, trastuzumab, and docetaxel compared with those treated without pertuzumab [47]. Here, ERBB2 is linked to inflammatory breast carcinoma.